# Cirrus


## Posts

- [Q&A: A Blavatnik Fellow’s Journey: Ying Kai Chan on Vision Science, Innovation, and Cirrus Therapeutics](https://cirrustx.com/qa-a-blavatnik-fellows-journey-ying-kai-chan-on-vision-science-innovation-and-cirrus-therapeutics/): During his time as a Blavatnik Fellow, Ying Kai Chan co-founded Cirrus Therapeutics, a company developing first-in-class and best-in-classs ocular medicines, which just recently celebrated an $11 million seed raise. We spoke with Kai about his path to HBS, the Fellowship’s role in shaping his entrepreneurial journey, and what’s ahead for Cirrus.
- [Cirrus Therapeutics Announces $11 million Seed Round to Advance Novel Ocular Gene Therapy Designed to Potentially Reverse Crucial Underlying Cause of Dry AMD](https://cirrustx.com/cirrus-therapeutics-announces-11-million-seed-round-to-advance-novel-ocular-gene-therapy-designed-to-potentially-reverse-crucial-underlying-cause-of-dry-amd/): Cirrus Therapeutics, an ocular immunology-focused biotech, announced today the close of an $11 million seed financing to advance its pipeline of gene and cell therapies aimed at improving quality of life and extending the ocular healthspan of patients with chronic blinding diseases. The round was led by ClavystBio, with participation from Polaris Partners and SEEDS.
- [Exclusive: Gene therapy startup launches with $11M to tackle aging disease of the eye](https://cirrustx.com/exclusive-gene-therapy-startup-launches-with-11m-to-tackle-aging-disease-of-the-eye/): Cirrus Therapeutics has raised an $11 million seed round toward its bet that altering the immune function of the eye using gene therapy can slow or potentially stop aging-related conditions that rob people of their sight.
- [Uveitis in Adults: A Review](https://cirrustx.com/8-2/): Uveitis is characterized by inflammation of the uvea and primarily affects adults aged 20 to 50 years. For noninfectious anterior uveitis, corticosteroid eyedrops are first-line treatment. For posterior noninfectious uveitis, disease-modifying antirheumatic drugs are first-line therapy; biologics su …
- [CEO Dr. Kai Chan Presents at Investing in Cures Summit 2025](https://cirrustx.com/7-2/): The Foundation Fighting Blindness and the Retinal Degeneration Fund (RD Fund) hosted their annual Investing in Cures Summit (ICS) on March 21 and 22, 2025 in Tampa to highlight the strong progress in development of treatments and cures for the entire spectrum of retinal degenerative diseases.
- [Treating age-related macular degeneration with Drs. Kai Chan and Andrew Dick (Cirrus Therapeutics)](https://cirrustx.com/treating-age-related-macular-degeneration-with-drs-kai-chan-and-andrew-dick-cirrus-therapeutics/): The "Aging Well Podcast" is about, well...aging. It's for people of all ages who are interested in aging successfully. The topics include the Spiritual, Physical, Intellectual, Emotional, and Social dimensions of wellness as they relate to living as well and as long as possible, as well as the financial, legal, and housing questions that everyone has about aging well. Do you have a question you want answered or topic you want discussed on the "Aging Well Podcast"? Send us an email to agingwell.podcast@gmail.com or record your question for us to use in an upcoming episode at following link: Record a message
- [Cambridge startup aims at age-related eye disease with gene therapy](https://cirrustx.com/cambridge-startup-aims-at-age-related-eye-disease-with-gene-therapy/): A Cambridge-based therapeutics company is working on a gene therapy aimed at a key protein in the eye that it says will help older adults against macular degeneration
- [Researchers unveil pioneering approach to combat age-related vision loss](https://cirrustx.com/researchers-unveil-pioneering-approach-to-combat-age-related-vision-loss-2/): June 5, 2024 (Cambridge, MA) – Cirrus Therapeutics, the University of Bristol, and London’s Global University Institute of Ophthalmology have discovered a revolutionary treatment for age-related macular degeneration (AMD), the leading cause of vision loss among older adults. Featured on the cover of the journal Science Translational Medicine, this breakthrough research reveals that boosting a specific protein, IRAK-M, in retinal cells could offer a new and highly effective therapy for AMD. AMD can severely impact a person’s vision. Patients suffering from AMD often start with blurred vision or seeing a black dot in their central vision, which can ultimately expand to the […]
- [Researchers unveil pioneering approach to combat age-related vision loss](https://cirrustx.com/researchers-unveil-pioneering-approach-to-combat-age-related-vision-loss/): Working together towards common goals strengthens bonds among community members.
- [Boosting Key Protein in Eye Cells Shows Promise in preventing AMD](https://cirrustx.com/boosting-key-protein-in-eye-cells-shows-promise-in-preventing-amd/): Increasing the levels of a key protein in eye cells may help protect against age-related macular degeneration (AMD), according to new research led by the University of Bristol.
- [Replenishing IRAK-M expression in retinal pigment epithelium attenuates outer retinal degeneration](https://cirrustx.com/replenishing-irak-m-expression-in-retinal-pigment-epithelium-attenuates-outer-retinal-degeneration/): Chronic inflammation is a constitutive component of many age-related diseases, including age-related macular degeneration (AMD). Here, we identified interleukin-1 receptor–associated kinase M (IRAK...

## Pages

- [Test](https://cirrustx.com/test/)
- [Privacy policy](https://cirrustx.com/privacy-policy/): Privacy policy Effective date: September 25, 2025Company: Cirrus Therapeutics, Inc. (“Cirrus,” “we,” “us,” or “our”)Contact: info@cirrustx.com | 780 Main Street, Cambridge, MA 02139    1) Scope and who we are This Privacy Policy explains how we collect, use, disclose, and protect personal information when you use cirrustx.com and related pages (the “Site”). It does not cover employee data or data we process under separate contracts. We are a life sciences company. The Site is informational and includes a simple “Contact Us” form. We do not provide medical care via the Site and we do not request or require protected health […]
- [Terms and conditions](https://cirrustx.com/terms-and-conditions/): Terms of Use Effective date: [Month Day, Year]Company: Cirrus Therapeutics, Inc. (“Cirrus,” “we,” “us,” or “our”)Website: cirrustx.com (the “Site”) 1) Acceptance of terms By accessing or using the Site, you agree to these Terms. If you do not agree, do not use the Site. We may update these Terms by posting a revised version. 2) Informational site; no medical advice The Site provides general information about our research and programs. It does not provide medical advice, diagnosis, or treatment. Always seek the advice of a qualified health provider regarding any medical condition. In an emergency, call your local emergency number. […]
- [Home](https://cirrustx.com/): Preserving Sight. Restoring Vision. Cirrus Therapeutics is leveraging ocular immunology to create transformative therapies, designed to extend ocular healthspan and redefine healthy aging for vision. A New Era in Ocular Immunology Cirrus Therapeutics is revolutionizing the treatment of age-related macular degeneration (AMD) with groundbreaking therapies that restore what aging takes away from our vision.   While traditional treatments chase symptoms and target single pathophysiological pathways, our pioneering research rejuvenates the eye’s defenses across multiple pathways, offering a preventative and restorative therapy with the potential to dramatically slow or even halt disease progression and reverse early signs of vision loss.   […]


[comment]: # (Generated by Hostinger Tools Plugin)